Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser
| Status: | Recruiting |
|---|---|
| Conditions: | Dermatology, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 10/7/2018 |
| Start Date: | May 11, 2017 |
| End Date: | October 31, 2019 |
| Contact: | Steven D Daveluy, MD |
| Email: | sdaveluy@med.wayne.edu |
| Phone: | 3134297854 |
Patients with bilateral hidradenitis in the axilla, groin and/or inframammary will be treated
on one side with the Alexandrite hair removal laser. The other side will serve as the
control.
on one side with the Alexandrite hair removal laser. The other side will serve as the
control.
Patients with bilateral disease will be chosen to participate in the study. Patients will be
advised to discontinue any prior systemic HS treatments two weeks before their first laser
session as a wash out period. One side of the patient will be chosen as the treatment side,
the other as an intrinsic control. Each participant will have a total of 4 treatments with
the laser, one treatment per month over the duration of 4 months. Patients will then
participate in a follow-up clinic visit two months after completion of their last treatment.
In between laser sessions, participants will be allowed to use benzoyl peroxide 10% wash as a
skin cleanser and clindamycin 1% solution or lotion as a topical therapy, both twice daily to
the treatment and control areas. At each visit, photographs will be taken of the lesions to
monitor progression and to serve as a comparison to the control side. The treatment side will
be treated with the laser and adjusted according to skin type as follows:
Skin type I-II (Fair Caucasian): Fluence: 30J/cm2 Skin type III (Darker Caucasian, light
Asian): Fluence: 25 J/cm2 Skin type IV (Mediterranean, Asian, Latin): Fluence: 18 J/cm2 Skin
type V (Light skinned black, Darker mediterranean): Fluence: 16J/cm2 Skin type VI (Dark
skinned black): Fluence 14 J/cm2
A spot size of 12 mm and a cryogen spray delay of 50/50 will be used for all treated
patients. The treatment area will not exceed 15cm x 15cm. If the patient cannot tolerate
treatment with the Alexandrite laser, the patient will be terminated from the study.
Following each treatment session, the patient will be given an ice pack to reduce any
discomfort the patient may experience as a result of treatment with the laser. Clinical
evaluation and photographs will determine improvement.
advised to discontinue any prior systemic HS treatments two weeks before their first laser
session as a wash out period. One side of the patient will be chosen as the treatment side,
the other as an intrinsic control. Each participant will have a total of 4 treatments with
the laser, one treatment per month over the duration of 4 months. Patients will then
participate in a follow-up clinic visit two months after completion of their last treatment.
In between laser sessions, participants will be allowed to use benzoyl peroxide 10% wash as a
skin cleanser and clindamycin 1% solution or lotion as a topical therapy, both twice daily to
the treatment and control areas. At each visit, photographs will be taken of the lesions to
monitor progression and to serve as a comparison to the control side. The treatment side will
be treated with the laser and adjusted according to skin type as follows:
Skin type I-II (Fair Caucasian): Fluence: 30J/cm2 Skin type III (Darker Caucasian, light
Asian): Fluence: 25 J/cm2 Skin type IV (Mediterranean, Asian, Latin): Fluence: 18 J/cm2 Skin
type V (Light skinned black, Darker mediterranean): Fluence: 16J/cm2 Skin type VI (Dark
skinned black): Fluence 14 J/cm2
A spot size of 12 mm and a cryogen spray delay of 50/50 will be used for all treated
patients. The treatment area will not exceed 15cm x 15cm. If the patient cannot tolerate
treatment with the Alexandrite laser, the patient will be terminated from the study.
Following each treatment session, the patient will be given an ice pack to reduce any
discomfort the patient may experience as a result of treatment with the laser. Clinical
evaluation and photographs will determine improvement.
Inclusion Criteria:
- Age 18-65
- Patients with Hidradenitis Suppurativa with bilateral and symmetric disease with one
or more anatomic sites of involvement.
Exclusion Criteria:
- Pregnant patients or patients planning to get pregnant during the time of the study
- Patients on systemic treatment for Hidradenitis Suppurativa
- Patients with photosensitivity disorders
- Patients unable to tolerate the laser treatments
- Intake of a photosensitive medication
We found this trial at
1
site
Dearborn, Michigan 48124
Principal Investigator: Steven D Daveluy, MD
Phone: 313-429-7854
Click here to add this to my saved trials
